225 related articles for article (PubMed ID: 19630844)
1. Increased patient co-payments and changes in PBS-subsidised prescription medicines dispensed in Western Australia.
Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
Aust N Z J Public Health; 2009 Jun; 33(3):246-52. PubMed ID: 19630844
[TBL] [Abstract][Full Text] [Related]
2. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671
[TBL] [Abstract][Full Text] [Related]
3. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals.
Andersson K; Bergström G; Petzold MG; Carlsten A
Health Policy; 2007 May; 81(2-3):376-84. PubMed ID: 16945449
[TBL] [Abstract][Full Text] [Related]
4. From the city to the bush: increases in patient co-payments for medicines have impacted on medicine use across Australia.
Kemp A; Glover J; Preen DB; Bulsara M; Semmens J; Roughead EE
Aust Health Rev; 2013 Feb; 37(1):4-10. PubMed ID: 23157851
[TBL] [Abstract][Full Text] [Related]
5. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
Clark BE; Siracuse MV; Garis RI
Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
[TBL] [Abstract][Full Text] [Related]
6. The Australian rise of esomeprazole-was expenditure on samples a contributor?
Kyle GJ; Nissen LM; Tett SE
Pharmacoepidemiol Drug Saf; 2009 Jan; 18(1):62-8. PubMed ID: 19111014
[TBL] [Abstract][Full Text] [Related]
7. Role of Cost on Failure to Access Prescribed Pharmaceuticals: The Case of Statins.
McRae I; van Gool K; Hall J; Yen L
Appl Health Econ Health Policy; 2017 Oct; 15(5):625-634. PubMed ID: 28660496
[TBL] [Abstract][Full Text] [Related]
8. How much do we spend on prescription medicines? Out-of-pocket costs for patients in Australia and other OECD countries.
Kemp A; Preen DB; Glover J; Semmens J; Roughead EE
Aust Health Rev; 2011 Aug; 35(3):341-9. PubMed ID: 21871197
[TBL] [Abstract][Full Text] [Related]
9. Moral hazard and prescription medicine use in Australia--the patient perspective.
Doran E; Robertson J; Henry D
Soc Sci Med; 2005 Apr; 60(7):1437-43. PubMed ID: 15652677
[TBL] [Abstract][Full Text] [Related]
10. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
McManus P; Birkett DJ; Dudley J; Stevens A
Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
[TBL] [Abstract][Full Text] [Related]
11. Impact of the phased abolition of co-payments on the utilisation of selected prescription medicines in Wales.
Alam MF; Cohen D; Dunstan F; Hughes D; Routledge P
Health Econ; 2018 Jan; 27(1):236-243. PubMed ID: 28685890
[TBL] [Abstract][Full Text] [Related]
12. Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia.
Seaman KL; Sanfilippo FM; Roughead EE; Bulsara MK; Kemp-Casey A; Bulsara C; Watts GF; Preen D
BMJ Open; 2017 Jun; 7(6):e013691. PubMed ID: 28637723
[TBL] [Abstract][Full Text] [Related]
13. Prescription drug utilization following patient co-payment changes in Australia.
McManus P; Donnelly N; Henry D; Hall W; Primrose J; Lindner J
Pharmacoepidemiol Drug Saf; 1996 Nov; 5(6):385-92. PubMed ID: 15073809
[TBL] [Abstract][Full Text] [Related]
14. The association of consumer cost-sharing and direct-to-consumer advertising with prescription drug use.
Hansen RA; Schommer JC; Cline RR; Hadsall RS; Schondelmeyer SW; Nyman JA
Res Social Adm Pharm; 2005 Jun; 1(2):139-57. PubMed ID: 17138472
[TBL] [Abstract][Full Text] [Related]
15. Changes in utilisation of anticholinergic drugs after initiation of cholinesterase inhibitors.
Robinson M; Rowett D; Leverton A; Mabbott V
Pharmacoepidemiol Drug Saf; 2009 Aug; 18(8):659-64. PubMed ID: 19548222
[TBL] [Abstract][Full Text] [Related]
16. Twenty-year trends in benzodiazepine dispensing in the Australian population.
Islam MM; Conigrave KM; Day CA; Nguyen Y; Haber PS
Intern Med J; 2014 Jan; 44(1):57-64. PubMed ID: 24450521
[TBL] [Abstract][Full Text] [Related]
17. Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing.
Barozzi N; Tett SE
Clin Ther; 2009 Apr; 31(4):849-61. PubMed ID: 19446158
[TBL] [Abstract][Full Text] [Related]
18. The impact of cost sharing of prescription drug expenditures on health care utilization by the elderly: own- and cross-price elasticities.
Li X; Guh D; Lacaille D; Esdaile J; Anis AH
Health Policy; 2007 Aug; 82(3):340-7. PubMed ID: 17134787
[TBL] [Abstract][Full Text] [Related]
19. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.
Fraeyman J; Verbelen M; Hens N; Van Hal G; De Loof H; Beutels P
Appl Health Econ Health Policy; 2013 Oct; 11(5):543-52. PubMed ID: 24062144
[TBL] [Abstract][Full Text] [Related]
20. Discounting of medicines in Australian community pharmacies.
Thai LP; Vitry AI; Moss JR
Aust Health Rev; 2014 Nov; 38(5):517-22. PubMed ID: 25099433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
